Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers

Improving patient outcome by personalized therapy involves a thorough understanding of an agent’s mechanism of action. β-Lapachone (clinical forms, Arq501/Arq761) has been developed to exploit dramatic cancer-specific elevations in the phase II detoxifying enzyme, NAD(P)H:quinone oxidoreductase (NQO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bey, Erik A., Reinicke, Kathryn E., Srougi, Melissa C., Varnes, Marie, Anderson, Vernon, Pink, John J., Li, Long Shan, Patel, Malina, Cao, Lifen, Moore, Zachary, Rommel, Amy, Boatman, Michael, Lewis, Cheryl, Euhus, David M., Bornmann, William G., Buchsbaum, Donald J., Spitz, Douglas R., Gao, Jinming, Boothman, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3807805/
https://ncbi.nlm.nih.gov/pubmed/23883585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0962
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados